Medical Devices & Consumables
Global Preeclampsia Therapeutic Market Research Report 2025
- Jan 09, 25
- ID: 797413
- Pages: 81
- Figures: 89
- Views: 1
The global market for Preeclampsia Therapeutic was valued at US$ 2510 million in the year 2024 and is projected to reach a revised size of US$ 3492 million by 2031, growing at a CAGR of 4.9% during the forecast period.
Medications to treat severe preeclampsia usually include: Antihypertensive drugs to lower blood pressure. Anticonvulsant medication, such as magnesium sulfate, to prevent seizures.
The global preeclampsia therapeutic market refers to the market for medications and therapies used in the treatment and management of preeclampsia, a pregnancy-related condition characterized by high blood pressure and damage to organs, most commonly the liver and kidneys. Preeclampsia can pose significant risks to both the mother and the fetus if left untreated.
The market for preeclampsia therapeutics is driven by several factors:
Increasing prevalence of preeclampsia: Preeclampsia is one of the leading causes of maternal and fetal morbidity and mortality worldwide. The increasing prevalence of preeclampsia, particularly in developing countries with limited access to adequate prenatal care, is driving the demand for effective therapeutics.
Rising awareness and diagnosis: There is a growing awareness of the signs and symptoms of preeclampsia, leading to improved diagnosis and timely intervention. Healthcare providers are implementing screening measures and diagnostic guidelines, which contribute to the overall growth of the market.
Advancements in treatment options: The market for preeclampsia therapeutics has witnessed advancements in treatment options, including antihypertensive medications, magnesium sulfate for seizures prophylaxis, and corticosteroids for fetal lung maturation. Ongoing research and development efforts are focused on developing targeted therapies to manage preeclampsia more effectively.
Government initiatives and healthcare policies: Governments across various regions have initiated programs and policies to improve maternal and child health, including the management of preeclampsia. These initiatives aim to enhance access to prenatal care, promote early detection, and provide affordable treatment options, which positively impact the market growth.
Collaborative research and development: Academic institutions, research organizations, and pharmaceutical companies are collaborating to develop novel therapeutic options for preeclampsia. These collaborations facilitate the exchange of knowledge and resources, expediting the development of effective treatment strategies.
Key players in the global preeclampsia therapeutic market include pharmaceutical companies such as Merck & Co., Inc., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., and AstraZeneca PLC. These companies are actively involved in research, clinical trials, and the development of innovative therapies for preeclampsia.
In conclusion, the global preeclampsia therapeutic market is driven by the increasing prevalence of preeclampsia, rising awareness and diagnosis, advancements in treatment options, government initiatives and healthcare policies, as well as collaborative research and development efforts. As the demand for effective and safe therapeutics for preeclampsia continues to rise, the market is expected to witness significant growth in the coming years.
This report aims to provide a comprehensive presentation of the global market for Preeclampsia Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Preeclampsia Therapeutic.
The Preeclampsia Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Preeclampsia Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Preeclampsia Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
LFB S.A.
A1M Pharma AB
AMAG Pharmaceuticals
VG Life Sciences,Inc.
PerkinElmer Inc.
Sera Prognostics,Inc.
DRG INSTRUMENTS GMBH
Roche Holding AG
Pluristem Therapeutics Inc.
Merck & Co., Inc
GlaxoSmithKline Plc
Novartis AG
Pfizer Inc
AstraZeneca PLC
Segment by Type
Antihypertensive Agents
Anticonvulsants
Antioxidants
Others
Segment by Application
Mild Preeclampsia
Severe Preeclampsia
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Preeclampsia Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Medications to treat severe preeclampsia usually include: Antihypertensive drugs to lower blood pressure. Anticonvulsant medication, such as magnesium sulfate, to prevent seizures.
The global preeclampsia therapeutic market refers to the market for medications and therapies used in the treatment and management of preeclampsia, a pregnancy-related condition characterized by high blood pressure and damage to organs, most commonly the liver and kidneys. Preeclampsia can pose significant risks to both the mother and the fetus if left untreated.
The market for preeclampsia therapeutics is driven by several factors:
Increasing prevalence of preeclampsia: Preeclampsia is one of the leading causes of maternal and fetal morbidity and mortality worldwide. The increasing prevalence of preeclampsia, particularly in developing countries with limited access to adequate prenatal care, is driving the demand for effective therapeutics.
Rising awareness and diagnosis: There is a growing awareness of the signs and symptoms of preeclampsia, leading to improved diagnosis and timely intervention. Healthcare providers are implementing screening measures and diagnostic guidelines, which contribute to the overall growth of the market.
Advancements in treatment options: The market for preeclampsia therapeutics has witnessed advancements in treatment options, including antihypertensive medications, magnesium sulfate for seizures prophylaxis, and corticosteroids for fetal lung maturation. Ongoing research and development efforts are focused on developing targeted therapies to manage preeclampsia more effectively.
Government initiatives and healthcare policies: Governments across various regions have initiated programs and policies to improve maternal and child health, including the management of preeclampsia. These initiatives aim to enhance access to prenatal care, promote early detection, and provide affordable treatment options, which positively impact the market growth.
Collaborative research and development: Academic institutions, research organizations, and pharmaceutical companies are collaborating to develop novel therapeutic options for preeclampsia. These collaborations facilitate the exchange of knowledge and resources, expediting the development of effective treatment strategies.
Key players in the global preeclampsia therapeutic market include pharmaceutical companies such as Merck & Co., Inc., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., and AstraZeneca PLC. These companies are actively involved in research, clinical trials, and the development of innovative therapies for preeclampsia.
In conclusion, the global preeclampsia therapeutic market is driven by the increasing prevalence of preeclampsia, rising awareness and diagnosis, advancements in treatment options, government initiatives and healthcare policies, as well as collaborative research and development efforts. As the demand for effective and safe therapeutics for preeclampsia continues to rise, the market is expected to witness significant growth in the coming years.
This report aims to provide a comprehensive presentation of the global market for Preeclampsia Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Preeclampsia Therapeutic.
The Preeclampsia Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Preeclampsia Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Preeclampsia Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
LFB S.A.
A1M Pharma AB
AMAG Pharmaceuticals
VG Life Sciences,Inc.
PerkinElmer Inc.
Sera Prognostics,Inc.
DRG INSTRUMENTS GMBH
Roche Holding AG
Pluristem Therapeutics Inc.
Merck & Co., Inc
GlaxoSmithKline Plc
Novartis AG
Pfizer Inc
AstraZeneca PLC
Segment by Type
Antihypertensive Agents
Anticonvulsants
Antioxidants
Others
Segment by Application
Mild Preeclampsia
Severe Preeclampsia
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Preeclampsia Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Preeclampsia Therapeutic Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antihypertensive Agents
1.2.3 Anticonvulsants
1.2.4 Antioxidants
1.2.5 Others
1.3 Market by Application
1.3.1 Global Preeclampsia Therapeutic Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Mild Preeclampsia
1.3.3 Severe Preeclampsia
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Preeclampsia Therapeutic Market Perspective (2020-2031)
2.2 Global Preeclampsia Therapeutic Growth Trends by Region
2.2.1 Global Preeclampsia Therapeutic Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Preeclampsia Therapeutic Historic Market Size by Region (2020-2025)
2.2.3 Preeclampsia Therapeutic Forecasted Market Size by Region (2026-2031)
2.3 Preeclampsia Therapeutic Market Dynamics
2.3.1 Preeclampsia Therapeutic Industry Trends
2.3.2 Preeclampsia Therapeutic Market Drivers
2.3.3 Preeclampsia Therapeutic Market Challenges
2.3.4 Preeclampsia Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Preeclampsia Therapeutic Players by Revenue
3.1.1 Global Top Preeclampsia Therapeutic Players by Revenue (2020-2025)
3.1.2 Global Preeclampsia Therapeutic Revenue Market Share by Players (2020-2025)
3.2 Global Preeclampsia Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Preeclampsia Therapeutic Revenue
3.4 Global Preeclampsia Therapeutic Market Concentration Ratio
3.4.1 Global Preeclampsia Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Preeclampsia Therapeutic Revenue in 2024
3.5 Global Key Players of Preeclampsia Therapeutic Head office and Area Served
3.6 Global Key Players of Preeclampsia Therapeutic, Product and Application
3.7 Global Key Players of Preeclampsia Therapeutic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Preeclampsia Therapeutic Breakdown Data by Type
4.1 Global Preeclampsia Therapeutic Historic Market Size by Type (2020-2025)
4.2 Global Preeclampsia Therapeutic Forecasted Market Size by Type (2026-2031)
5 Preeclampsia Therapeutic Breakdown Data by Application
5.1 Global Preeclampsia Therapeutic Historic Market Size by Application (2020-2025)
5.2 Global Preeclampsia Therapeutic Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Preeclampsia Therapeutic Market Size (2020-2031)
6.2 North America Preeclampsia Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Preeclampsia Therapeutic Market Size by Country (2020-2025)
6.4 North America Preeclampsia Therapeutic Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Preeclampsia Therapeutic Market Size (2020-2031)
7.2 Europe Preeclampsia Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Preeclampsia Therapeutic Market Size by Country (2020-2025)
7.4 Europe Preeclampsia Therapeutic Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Preeclampsia Therapeutic Market Size (2020-2031)
8.2 Asia-Pacific Preeclampsia Therapeutic Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Preeclampsia Therapeutic Market Size by Region (2020-2025)
8.4 Asia-Pacific Preeclampsia Therapeutic Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Preeclampsia Therapeutic Market Size (2020-2031)
9.2 Latin America Preeclampsia Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Preeclampsia Therapeutic Market Size by Country (2020-2025)
9.4 Latin America Preeclampsia Therapeutic Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Preeclampsia Therapeutic Market Size (2020-2031)
10.2 Middle East & Africa Preeclampsia Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Preeclampsia Therapeutic Market Size by Country (2020-2025)
10.4 Middle East & Africa Preeclampsia Therapeutic Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 LFB S.A.
11.1.1 LFB S.A. Company Details
11.1.2 LFB S.A. Business Overview
11.1.3 LFB S.A. Preeclampsia Therapeutic Introduction
11.1.4 LFB S.A. Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.1.5 LFB S.A. Recent Development
11.2 A1M Pharma AB
11.2.1 A1M Pharma AB Company Details
11.2.2 A1M Pharma AB Business Overview
11.2.3 A1M Pharma AB Preeclampsia Therapeutic Introduction
11.2.4 A1M Pharma AB Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.2.5 A1M Pharma AB Recent Development
11.3 AMAG Pharmaceuticals
11.3.1 AMAG Pharmaceuticals Company Details
11.3.2 AMAG Pharmaceuticals Business Overview
11.3.3 AMAG Pharmaceuticals Preeclampsia Therapeutic Introduction
11.3.4 AMAG Pharmaceuticals Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.3.5 AMAG Pharmaceuticals Recent Development
11.4 VG Life Sciences,Inc.
11.4.1 VG Life Sciences,Inc. Company Details
11.4.2 VG Life Sciences,Inc. Business Overview
11.4.3 VG Life Sciences,Inc. Preeclampsia Therapeutic Introduction
11.4.4 VG Life Sciences,Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.4.5 VG Life Sciences,Inc. Recent Development
11.5 PerkinElmer Inc.
11.5.1 PerkinElmer Inc. Company Details
11.5.2 PerkinElmer Inc. Business Overview
11.5.3 PerkinElmer Inc. Preeclampsia Therapeutic Introduction
11.5.4 PerkinElmer Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.5.5 PerkinElmer Inc. Recent Development
11.6 Sera Prognostics,Inc.
11.6.1 Sera Prognostics,Inc. Company Details
11.6.2 Sera Prognostics,Inc. Business Overview
11.6.3 Sera Prognostics,Inc. Preeclampsia Therapeutic Introduction
11.6.4 Sera Prognostics,Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.6.5 Sera Prognostics,Inc. Recent Development
11.7 DRG INSTRUMENTS GMBH
11.7.1 DRG INSTRUMENTS GMBH Company Details
11.7.2 DRG INSTRUMENTS GMBH Business Overview
11.7.3 DRG INSTRUMENTS GMBH Preeclampsia Therapeutic Introduction
11.7.4 DRG INSTRUMENTS GMBH Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.7.5 DRG INSTRUMENTS GMBH Recent Development
11.8 Roche Holding AG
11.8.1 Roche Holding AG Company Details
11.8.2 Roche Holding AG Business Overview
11.8.3 Roche Holding AG Preeclampsia Therapeutic Introduction
11.8.4 Roche Holding AG Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.8.5 Roche Holding AG Recent Development
11.9 Pluristem Therapeutics Inc.
11.9.1 Pluristem Therapeutics Inc. Company Details
11.9.2 Pluristem Therapeutics Inc. Business Overview
11.9.3 Pluristem Therapeutics Inc. Preeclampsia Therapeutic Introduction
11.9.4 Pluristem Therapeutics Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.9.5 Pluristem Therapeutics Inc. Recent Development
11.10 Merck & Co., Inc
11.10.1 Merck & Co., Inc Company Details
11.10.2 Merck & Co., Inc Business Overview
11.10.3 Merck & Co., Inc Preeclampsia Therapeutic Introduction
11.10.4 Merck & Co., Inc Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.10.5 Merck & Co., Inc Recent Development
11.11 GlaxoSmithKline Plc
11.11.1 GlaxoSmithKline Plc Company Details
11.11.2 GlaxoSmithKline Plc Business Overview
11.11.3 GlaxoSmithKline Plc Preeclampsia Therapeutic Introduction
11.11.4 GlaxoSmithKline Plc Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.11.5 GlaxoSmithKline Plc Recent Development
11.12 Novartis AG
11.12.1 Novartis AG Company Details
11.12.2 Novartis AG Business Overview
11.12.3 Novartis AG Preeclampsia Therapeutic Introduction
11.12.4 Novartis AG Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.12.5 Novartis AG Recent Development
11.13 Pfizer Inc
11.13.1 Pfizer Inc Company Details
11.13.2 Pfizer Inc Business Overview
11.13.3 Pfizer Inc Preeclampsia Therapeutic Introduction
11.13.4 Pfizer Inc Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.13.5 Pfizer Inc Recent Development
11.14 AstraZeneca PLC
11.14.1 AstraZeneca PLC Company Details
11.14.2 AstraZeneca PLC Business Overview
11.14.3 AstraZeneca PLC Preeclampsia Therapeutic Introduction
11.14.4 AstraZeneca PLC Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.14.5 AstraZeneca PLC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Preeclampsia Therapeutic Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antihypertensive Agents
1.2.3 Anticonvulsants
1.2.4 Antioxidants
1.2.5 Others
1.3 Market by Application
1.3.1 Global Preeclampsia Therapeutic Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Mild Preeclampsia
1.3.3 Severe Preeclampsia
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Preeclampsia Therapeutic Market Perspective (2020-2031)
2.2 Global Preeclampsia Therapeutic Growth Trends by Region
2.2.1 Global Preeclampsia Therapeutic Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Preeclampsia Therapeutic Historic Market Size by Region (2020-2025)
2.2.3 Preeclampsia Therapeutic Forecasted Market Size by Region (2026-2031)
2.3 Preeclampsia Therapeutic Market Dynamics
2.3.1 Preeclampsia Therapeutic Industry Trends
2.3.2 Preeclampsia Therapeutic Market Drivers
2.3.3 Preeclampsia Therapeutic Market Challenges
2.3.4 Preeclampsia Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Preeclampsia Therapeutic Players by Revenue
3.1.1 Global Top Preeclampsia Therapeutic Players by Revenue (2020-2025)
3.1.2 Global Preeclampsia Therapeutic Revenue Market Share by Players (2020-2025)
3.2 Global Preeclampsia Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Preeclampsia Therapeutic Revenue
3.4 Global Preeclampsia Therapeutic Market Concentration Ratio
3.4.1 Global Preeclampsia Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Preeclampsia Therapeutic Revenue in 2024
3.5 Global Key Players of Preeclampsia Therapeutic Head office and Area Served
3.6 Global Key Players of Preeclampsia Therapeutic, Product and Application
3.7 Global Key Players of Preeclampsia Therapeutic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Preeclampsia Therapeutic Breakdown Data by Type
4.1 Global Preeclampsia Therapeutic Historic Market Size by Type (2020-2025)
4.2 Global Preeclampsia Therapeutic Forecasted Market Size by Type (2026-2031)
5 Preeclampsia Therapeutic Breakdown Data by Application
5.1 Global Preeclampsia Therapeutic Historic Market Size by Application (2020-2025)
5.2 Global Preeclampsia Therapeutic Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Preeclampsia Therapeutic Market Size (2020-2031)
6.2 North America Preeclampsia Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Preeclampsia Therapeutic Market Size by Country (2020-2025)
6.4 North America Preeclampsia Therapeutic Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Preeclampsia Therapeutic Market Size (2020-2031)
7.2 Europe Preeclampsia Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Preeclampsia Therapeutic Market Size by Country (2020-2025)
7.4 Europe Preeclampsia Therapeutic Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Preeclampsia Therapeutic Market Size (2020-2031)
8.2 Asia-Pacific Preeclampsia Therapeutic Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Preeclampsia Therapeutic Market Size by Region (2020-2025)
8.4 Asia-Pacific Preeclampsia Therapeutic Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Preeclampsia Therapeutic Market Size (2020-2031)
9.2 Latin America Preeclampsia Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Preeclampsia Therapeutic Market Size by Country (2020-2025)
9.4 Latin America Preeclampsia Therapeutic Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Preeclampsia Therapeutic Market Size (2020-2031)
10.2 Middle East & Africa Preeclampsia Therapeutic Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Preeclampsia Therapeutic Market Size by Country (2020-2025)
10.4 Middle East & Africa Preeclampsia Therapeutic Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 LFB S.A.
11.1.1 LFB S.A. Company Details
11.1.2 LFB S.A. Business Overview
11.1.3 LFB S.A. Preeclampsia Therapeutic Introduction
11.1.4 LFB S.A. Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.1.5 LFB S.A. Recent Development
11.2 A1M Pharma AB
11.2.1 A1M Pharma AB Company Details
11.2.2 A1M Pharma AB Business Overview
11.2.3 A1M Pharma AB Preeclampsia Therapeutic Introduction
11.2.4 A1M Pharma AB Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.2.5 A1M Pharma AB Recent Development
11.3 AMAG Pharmaceuticals
11.3.1 AMAG Pharmaceuticals Company Details
11.3.2 AMAG Pharmaceuticals Business Overview
11.3.3 AMAG Pharmaceuticals Preeclampsia Therapeutic Introduction
11.3.4 AMAG Pharmaceuticals Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.3.5 AMAG Pharmaceuticals Recent Development
11.4 VG Life Sciences,Inc.
11.4.1 VG Life Sciences,Inc. Company Details
11.4.2 VG Life Sciences,Inc. Business Overview
11.4.3 VG Life Sciences,Inc. Preeclampsia Therapeutic Introduction
11.4.4 VG Life Sciences,Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.4.5 VG Life Sciences,Inc. Recent Development
11.5 PerkinElmer Inc.
11.5.1 PerkinElmer Inc. Company Details
11.5.2 PerkinElmer Inc. Business Overview
11.5.3 PerkinElmer Inc. Preeclampsia Therapeutic Introduction
11.5.4 PerkinElmer Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.5.5 PerkinElmer Inc. Recent Development
11.6 Sera Prognostics,Inc.
11.6.1 Sera Prognostics,Inc. Company Details
11.6.2 Sera Prognostics,Inc. Business Overview
11.6.3 Sera Prognostics,Inc. Preeclampsia Therapeutic Introduction
11.6.4 Sera Prognostics,Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.6.5 Sera Prognostics,Inc. Recent Development
11.7 DRG INSTRUMENTS GMBH
11.7.1 DRG INSTRUMENTS GMBH Company Details
11.7.2 DRG INSTRUMENTS GMBH Business Overview
11.7.3 DRG INSTRUMENTS GMBH Preeclampsia Therapeutic Introduction
11.7.4 DRG INSTRUMENTS GMBH Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.7.5 DRG INSTRUMENTS GMBH Recent Development
11.8 Roche Holding AG
11.8.1 Roche Holding AG Company Details
11.8.2 Roche Holding AG Business Overview
11.8.3 Roche Holding AG Preeclampsia Therapeutic Introduction
11.8.4 Roche Holding AG Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.8.5 Roche Holding AG Recent Development
11.9 Pluristem Therapeutics Inc.
11.9.1 Pluristem Therapeutics Inc. Company Details
11.9.2 Pluristem Therapeutics Inc. Business Overview
11.9.3 Pluristem Therapeutics Inc. Preeclampsia Therapeutic Introduction
11.9.4 Pluristem Therapeutics Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.9.5 Pluristem Therapeutics Inc. Recent Development
11.10 Merck & Co., Inc
11.10.1 Merck & Co., Inc Company Details
11.10.2 Merck & Co., Inc Business Overview
11.10.3 Merck & Co., Inc Preeclampsia Therapeutic Introduction
11.10.4 Merck & Co., Inc Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.10.5 Merck & Co., Inc Recent Development
11.11 GlaxoSmithKline Plc
11.11.1 GlaxoSmithKline Plc Company Details
11.11.2 GlaxoSmithKline Plc Business Overview
11.11.3 GlaxoSmithKline Plc Preeclampsia Therapeutic Introduction
11.11.4 GlaxoSmithKline Plc Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.11.5 GlaxoSmithKline Plc Recent Development
11.12 Novartis AG
11.12.1 Novartis AG Company Details
11.12.2 Novartis AG Business Overview
11.12.3 Novartis AG Preeclampsia Therapeutic Introduction
11.12.4 Novartis AG Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.12.5 Novartis AG Recent Development
11.13 Pfizer Inc
11.13.1 Pfizer Inc Company Details
11.13.2 Pfizer Inc Business Overview
11.13.3 Pfizer Inc Preeclampsia Therapeutic Introduction
11.13.4 Pfizer Inc Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.13.5 Pfizer Inc Recent Development
11.14 AstraZeneca PLC
11.14.1 AstraZeneca PLC Company Details
11.14.2 AstraZeneca PLC Business Overview
11.14.3 AstraZeneca PLC Preeclampsia Therapeutic Introduction
11.14.4 AstraZeneca PLC Revenue in Preeclampsia Therapeutic Business (2020-2025)
11.14.5 AstraZeneca PLC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Preeclampsia Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Antihypertensive Agents
Table 3. Key Players of Anticonvulsants
Table 4. Key Players of Antioxidants
Table 5. Key Players of Others
Table 6. Global Preeclampsia Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Preeclampsia Therapeutic Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Preeclampsia Therapeutic Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Preeclampsia Therapeutic Market Share by Region (2020-2025)
Table 10. Global Preeclampsia Therapeutic Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Preeclampsia Therapeutic Market Share by Region (2026-2031)
Table 12. Preeclampsia Therapeutic Market Trends
Table 13. Preeclampsia Therapeutic Market Drivers
Table 14. Preeclampsia Therapeutic Market Challenges
Table 15. Preeclampsia Therapeutic Market Restraints
Table 16. Global Preeclampsia Therapeutic Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Preeclampsia Therapeutic Market Share by Players (2020-2025)
Table 18. Global Top Preeclampsia Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Preeclampsia Therapeutic as of 2024)
Table 19. Ranking of Global Top Preeclampsia Therapeutic Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Preeclampsia Therapeutic Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Preeclampsia Therapeutic, Headquarters and Area Served
Table 22. Global Key Players of Preeclampsia Therapeutic, Product and Application
Table 23. Global Key Players of Preeclampsia Therapeutic, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Preeclampsia Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Preeclampsia Therapeutic Revenue Market Share by Type (2020-2025)
Table 27. Global Preeclampsia Therapeutic Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Preeclampsia Therapeutic Revenue Market Share by Type (2026-2031)
Table 29. Global Preeclampsia Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Preeclampsia Therapeutic Revenue Market Share by Application (2020-2025)
Table 31. Global Preeclampsia Therapeutic Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Preeclampsia Therapeutic Revenue Market Share by Application (2026-2031)
Table 33. North America Preeclampsia Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Preeclampsia Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Preeclampsia Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Preeclampsia Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Preeclampsia Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Preeclampsia Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Preeclampsia Therapeutic Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Preeclampsia Therapeutic Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Preeclampsia Therapeutic Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Preeclampsia Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Preeclampsia Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Preeclampsia Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Preeclampsia Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Preeclampsia Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Preeclampsia Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 48. LFB S.A. Company Details
Table 49. LFB S.A. Business Overview
Table 50. LFB S.A. Preeclampsia Therapeutic Product
Table 51. LFB S.A. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 52. LFB S.A. Recent Development
Table 53. A1M Pharma AB Company Details
Table 54. A1M Pharma AB Business Overview
Table 55. A1M Pharma AB Preeclampsia Therapeutic Product
Table 56. A1M Pharma AB Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 57. A1M Pharma AB Recent Development
Table 58. AMAG Pharmaceuticals Company Details
Table 59. AMAG Pharmaceuticals Business Overview
Table 60. AMAG Pharmaceuticals Preeclampsia Therapeutic Product
Table 61. AMAG Pharmaceuticals Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 62. AMAG Pharmaceuticals Recent Development
Table 63. VG Life Sciences,Inc. Company Details
Table 64. VG Life Sciences,Inc. Business Overview
Table 65. VG Life Sciences,Inc. Preeclampsia Therapeutic Product
Table 66. VG Life Sciences,Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 67. VG Life Sciences,Inc. Recent Development
Table 68. PerkinElmer Inc. Company Details
Table 69. PerkinElmer Inc. Business Overview
Table 70. PerkinElmer Inc. Preeclampsia Therapeutic Product
Table 71. PerkinElmer Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 72. PerkinElmer Inc. Recent Development
Table 73. Sera Prognostics,Inc. Company Details
Table 74. Sera Prognostics,Inc. Business Overview
Table 75. Sera Prognostics,Inc. Preeclampsia Therapeutic Product
Table 76. Sera Prognostics,Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 77. Sera Prognostics,Inc. Recent Development
Table 78. DRG INSTRUMENTS GMBH Company Details
Table 79. DRG INSTRUMENTS GMBH Business Overview
Table 80. DRG INSTRUMENTS GMBH Preeclampsia Therapeutic Product
Table 81. DRG INSTRUMENTS GMBH Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 82. DRG INSTRUMENTS GMBH Recent Development
Table 83. Roche Holding AG Company Details
Table 84. Roche Holding AG Business Overview
Table 85. Roche Holding AG Preeclampsia Therapeutic Product
Table 86. Roche Holding AG Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 87. Roche Holding AG Recent Development
Table 88. Pluristem Therapeutics Inc. Company Details
Table 89. Pluristem Therapeutics Inc. Business Overview
Table 90. Pluristem Therapeutics Inc. Preeclampsia Therapeutic Product
Table 91. Pluristem Therapeutics Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 92. Pluristem Therapeutics Inc. Recent Development
Table 93. Merck & Co., Inc Company Details
Table 94. Merck & Co., Inc Business Overview
Table 95. Merck & Co., Inc Preeclampsia Therapeutic Product
Table 96. Merck & Co., Inc Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 97. Merck & Co., Inc Recent Development
Table 98. GlaxoSmithKline Plc Company Details
Table 99. GlaxoSmithKline Plc Business Overview
Table 100. GlaxoSmithKline Plc Preeclampsia Therapeutic Product
Table 101. GlaxoSmithKline Plc Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 102. GlaxoSmithKline Plc Recent Development
Table 103. Novartis AG Company Details
Table 104. Novartis AG Business Overview
Table 105. Novartis AG Preeclampsia Therapeutic Product
Table 106. Novartis AG Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 107. Novartis AG Recent Development
Table 108. Pfizer Inc Company Details
Table 109. Pfizer Inc Business Overview
Table 110. Pfizer Inc Preeclampsia Therapeutic Product
Table 111. Pfizer Inc Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 112. Pfizer Inc Recent Development
Table 113. AstraZeneca PLC Company Details
Table 114. AstraZeneca PLC Business Overview
Table 115. AstraZeneca PLC Preeclampsia Therapeutic Product
Table 116. AstraZeneca PLC Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 117. AstraZeneca PLC Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 121. Authors List of This Report
List of Figures
Figure 1. Preeclampsia Therapeutic Picture
Figure 2. Global Preeclampsia Therapeutic Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Preeclampsia Therapeutic Market Share by Type: 2024 VS 2031
Figure 4. Antihypertensive Agents Features
Figure 5. Anticonvulsants Features
Figure 6. Antioxidants Features
Figure 7. Others Features
Figure 8. Global Preeclampsia Therapeutic Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Preeclampsia Therapeutic Market Share by Application: 2024 VS 2031
Figure 10. Mild Preeclampsia Case Studies
Figure 11. Severe Preeclampsia Case Studies
Figure 12. Others Case Studies
Figure 13. Preeclampsia Therapeutic Report Years Considered
Figure 14. Global Preeclampsia Therapeutic Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Preeclampsia Therapeutic Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Preeclampsia Therapeutic Market Share by Region: 2024 VS 2031
Figure 17. Global Preeclampsia Therapeutic Market Share by Players in 2024
Figure 18. Global Top Preeclampsia Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Preeclampsia Therapeutic as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Preeclampsia Therapeutic Revenue in 2024
Figure 20. North America Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Preeclampsia Therapeutic Market Share by Country (2020-2031)
Figure 22. United States Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Preeclampsia Therapeutic Market Share by Country (2020-2031)
Figure 26. Germany Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Preeclampsia Therapeutic Market Share by Region (2020-2031)
Figure 34. China Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Preeclampsia Therapeutic Market Share by Country (2020-2031)
Figure 42. Mexico Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Preeclampsia Therapeutic Market Share by Country (2020-2031)
Figure 46. Turkey Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. LFB S.A. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 50. A1M Pharma AB Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 51. AMAG Pharmaceuticals Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 52. VG Life Sciences,Inc. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 53. PerkinElmer Inc. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 54. Sera Prognostics,Inc. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 55. DRG INSTRUMENTS GMBH Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 56. Roche Holding AG Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 57. Pluristem Therapeutics Inc. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 58. Merck & Co., Inc Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 59. GlaxoSmithKline Plc Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 60. Novartis AG Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 61. Pfizer Inc Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 62. AstraZeneca PLC Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Table 1. Global Preeclampsia Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Antihypertensive Agents
Table 3. Key Players of Anticonvulsants
Table 4. Key Players of Antioxidants
Table 5. Key Players of Others
Table 6. Global Preeclampsia Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Preeclampsia Therapeutic Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Preeclampsia Therapeutic Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Preeclampsia Therapeutic Market Share by Region (2020-2025)
Table 10. Global Preeclampsia Therapeutic Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Preeclampsia Therapeutic Market Share by Region (2026-2031)
Table 12. Preeclampsia Therapeutic Market Trends
Table 13. Preeclampsia Therapeutic Market Drivers
Table 14. Preeclampsia Therapeutic Market Challenges
Table 15. Preeclampsia Therapeutic Market Restraints
Table 16. Global Preeclampsia Therapeutic Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Preeclampsia Therapeutic Market Share by Players (2020-2025)
Table 18. Global Top Preeclampsia Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Preeclampsia Therapeutic as of 2024)
Table 19. Ranking of Global Top Preeclampsia Therapeutic Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Preeclampsia Therapeutic Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Preeclampsia Therapeutic, Headquarters and Area Served
Table 22. Global Key Players of Preeclampsia Therapeutic, Product and Application
Table 23. Global Key Players of Preeclampsia Therapeutic, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Preeclampsia Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Preeclampsia Therapeutic Revenue Market Share by Type (2020-2025)
Table 27. Global Preeclampsia Therapeutic Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Preeclampsia Therapeutic Revenue Market Share by Type (2026-2031)
Table 29. Global Preeclampsia Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Preeclampsia Therapeutic Revenue Market Share by Application (2020-2025)
Table 31. Global Preeclampsia Therapeutic Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Preeclampsia Therapeutic Revenue Market Share by Application (2026-2031)
Table 33. North America Preeclampsia Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Preeclampsia Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Preeclampsia Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Preeclampsia Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Preeclampsia Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Preeclampsia Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Preeclampsia Therapeutic Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Preeclampsia Therapeutic Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Preeclampsia Therapeutic Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Preeclampsia Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Preeclampsia Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Preeclampsia Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Preeclampsia Therapeutic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Preeclampsia Therapeutic Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Preeclampsia Therapeutic Market Size by Country (2026-2031) & (US$ Million)
Table 48. LFB S.A. Company Details
Table 49. LFB S.A. Business Overview
Table 50. LFB S.A. Preeclampsia Therapeutic Product
Table 51. LFB S.A. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 52. LFB S.A. Recent Development
Table 53. A1M Pharma AB Company Details
Table 54. A1M Pharma AB Business Overview
Table 55. A1M Pharma AB Preeclampsia Therapeutic Product
Table 56. A1M Pharma AB Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 57. A1M Pharma AB Recent Development
Table 58. AMAG Pharmaceuticals Company Details
Table 59. AMAG Pharmaceuticals Business Overview
Table 60. AMAG Pharmaceuticals Preeclampsia Therapeutic Product
Table 61. AMAG Pharmaceuticals Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 62. AMAG Pharmaceuticals Recent Development
Table 63. VG Life Sciences,Inc. Company Details
Table 64. VG Life Sciences,Inc. Business Overview
Table 65. VG Life Sciences,Inc. Preeclampsia Therapeutic Product
Table 66. VG Life Sciences,Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 67. VG Life Sciences,Inc. Recent Development
Table 68. PerkinElmer Inc. Company Details
Table 69. PerkinElmer Inc. Business Overview
Table 70. PerkinElmer Inc. Preeclampsia Therapeutic Product
Table 71. PerkinElmer Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 72. PerkinElmer Inc. Recent Development
Table 73. Sera Prognostics,Inc. Company Details
Table 74. Sera Prognostics,Inc. Business Overview
Table 75. Sera Prognostics,Inc. Preeclampsia Therapeutic Product
Table 76. Sera Prognostics,Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 77. Sera Prognostics,Inc. Recent Development
Table 78. DRG INSTRUMENTS GMBH Company Details
Table 79. DRG INSTRUMENTS GMBH Business Overview
Table 80. DRG INSTRUMENTS GMBH Preeclampsia Therapeutic Product
Table 81. DRG INSTRUMENTS GMBH Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 82. DRG INSTRUMENTS GMBH Recent Development
Table 83. Roche Holding AG Company Details
Table 84. Roche Holding AG Business Overview
Table 85. Roche Holding AG Preeclampsia Therapeutic Product
Table 86. Roche Holding AG Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 87. Roche Holding AG Recent Development
Table 88. Pluristem Therapeutics Inc. Company Details
Table 89. Pluristem Therapeutics Inc. Business Overview
Table 90. Pluristem Therapeutics Inc. Preeclampsia Therapeutic Product
Table 91. Pluristem Therapeutics Inc. Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 92. Pluristem Therapeutics Inc. Recent Development
Table 93. Merck & Co., Inc Company Details
Table 94. Merck & Co., Inc Business Overview
Table 95. Merck & Co., Inc Preeclampsia Therapeutic Product
Table 96. Merck & Co., Inc Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 97. Merck & Co., Inc Recent Development
Table 98. GlaxoSmithKline Plc Company Details
Table 99. GlaxoSmithKline Plc Business Overview
Table 100. GlaxoSmithKline Plc Preeclampsia Therapeutic Product
Table 101. GlaxoSmithKline Plc Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 102. GlaxoSmithKline Plc Recent Development
Table 103. Novartis AG Company Details
Table 104. Novartis AG Business Overview
Table 105. Novartis AG Preeclampsia Therapeutic Product
Table 106. Novartis AG Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 107. Novartis AG Recent Development
Table 108. Pfizer Inc Company Details
Table 109. Pfizer Inc Business Overview
Table 110. Pfizer Inc Preeclampsia Therapeutic Product
Table 111. Pfizer Inc Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 112. Pfizer Inc Recent Development
Table 113. AstraZeneca PLC Company Details
Table 114. AstraZeneca PLC Business Overview
Table 115. AstraZeneca PLC Preeclampsia Therapeutic Product
Table 116. AstraZeneca PLC Revenue in Preeclampsia Therapeutic Business (2020-2025) & (US$ Million)
Table 117. AstraZeneca PLC Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 121. Authors List of This Report
List of Figures
Figure 1. Preeclampsia Therapeutic Picture
Figure 2. Global Preeclampsia Therapeutic Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Preeclampsia Therapeutic Market Share by Type: 2024 VS 2031
Figure 4. Antihypertensive Agents Features
Figure 5. Anticonvulsants Features
Figure 6. Antioxidants Features
Figure 7. Others Features
Figure 8. Global Preeclampsia Therapeutic Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Preeclampsia Therapeutic Market Share by Application: 2024 VS 2031
Figure 10. Mild Preeclampsia Case Studies
Figure 11. Severe Preeclampsia Case Studies
Figure 12. Others Case Studies
Figure 13. Preeclampsia Therapeutic Report Years Considered
Figure 14. Global Preeclampsia Therapeutic Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Preeclampsia Therapeutic Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Preeclampsia Therapeutic Market Share by Region: 2024 VS 2031
Figure 17. Global Preeclampsia Therapeutic Market Share by Players in 2024
Figure 18. Global Top Preeclampsia Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Preeclampsia Therapeutic as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Preeclampsia Therapeutic Revenue in 2024
Figure 20. North America Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Preeclampsia Therapeutic Market Share by Country (2020-2031)
Figure 22. United States Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Preeclampsia Therapeutic Market Share by Country (2020-2031)
Figure 26. Germany Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Preeclampsia Therapeutic Market Share by Region (2020-2031)
Figure 34. China Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Preeclampsia Therapeutic Market Share by Country (2020-2031)
Figure 42. Mexico Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Preeclampsia Therapeutic Market Share by Country (2020-2031)
Figure 46. Turkey Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Preeclampsia Therapeutic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. LFB S.A. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 50. A1M Pharma AB Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 51. AMAG Pharmaceuticals Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 52. VG Life Sciences,Inc. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 53. PerkinElmer Inc. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 54. Sera Prognostics,Inc. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 55. DRG INSTRUMENTS GMBH Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 56. Roche Holding AG Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 57. Pluristem Therapeutics Inc. Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 58. Merck & Co., Inc Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 59. GlaxoSmithKline Plc Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 60. Novartis AG Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 61. Pfizer Inc Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 62. AstraZeneca PLC Revenue Growth Rate in Preeclampsia Therapeutic Business (2020-2025)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Food Grade FIBC Bulk Bags Market Research Report 2025
Jan 09, 25
Global Standard FIBC Market Research Report 2025
Jan 09, 25
Global Mammoplasty Retractors Market Research Report 2025
Jan 09, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232